Concord Medical: The application for the market approval of the injection Rui Kang Qu Tu Zhen Duan Kang monoclonal antibody has been accepted and will be given priority review.

Hengrui Pharmaceuticals announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received the "Acceptance Notice" issued by the National Medical Products Administration for the application for marketing approval of the injectable drug RC-2025 monoclonal antibody. The drug was approved for the treatment of specific lung cancer in China in May 2025, and this new indication is for the treatment of HER2-positive colorectal cancer in adult patients who have failed treatment with oxaliplatin and other therapies. As of now, the cumulative research and development investment for the project is approximately 1.773 billion yuan. There are uncertainties in the research and development process for the drug to be marketed, and the company will disclose any progress in a timely manner.